Vitaxin
Vitaxin is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3. It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis. It is the developmental precursor of Etaracizumab. Both are derived from the mouse antibody LM609.
Vitaxin is safe for humans. It has little effect on advanced cancer.
